Fox Steven J, Schick Vadim
Office of Post & Schell, PC, Washington, DC, USA.
J Healthc Inf Manag. 2010 Winter;24(1):36-42.
In this economic climate, healthcare providers may face extraordinary challenges securing financing for health IT projects, especially ones required to capitalize on the incentives in ARRA. Vendor financing may be the best option for many such providers. While such arrangements may often seem a win-win for both parties, providers should be aware of the many potential pitfalls inherent in vendorfinanced deals, including: 1.) additional pressure from vendors to accept their standard contractual terms and conditions because vendors have much more leverage if they are also the creditor in the transaction; 2.) failing to obtain necessary warranties and representations from vendors that their systems will comply with all relevant requirements under ARRA and will permit the provider to achieve meaningful use; and 3.) dealing with problems arising if the vendors' product fails to achieve certification, or the provider fails to achieve "meaningful use" in a timely manner.
在这种经济环境下，医疗保健供应商在为健康信息技术项目获取资金时可能面临巨大挑战，尤其是那些利用《美国复苏与再投资法案》（ARRA）中的激励措施所必需的项目。对许多此类供应商而言，供应商融资可能是最佳选择。虽然此类安排对双方来说往往看似双赢，但供应商应意识到供应商融资交易中固有的许多潜在陷阱，包括：1. 供应商施加额外压力，要求接受其标准合同条款和条件，因为如果供应商也是交易中的债权人，他们就拥有更大的影响力；2. 未能从供应商处获得必要的保证和声明，即其系统将符合ARRA规定的所有相关要求，并能使供应商实现有效使用；3. 处理因供应商产品未能获得认证，或供应商未能及时实现“有效使用”而产生的问题。
